Skip to main content
WuXi Biologics (Cayman) Inc. logo

WuXi Biologics (Cayman) Inc. — Investor Relations & Filings

Ticker · 2269 ISIN · KYG970081173 LEI · 5493001TD2TH6VDTJU11 HKEX Manufacturing
Open in API
Filings indexed 551 across all filing types
Latest filing 2026-05-31 Investor Presentation
Country KY Cayman Islands
Listing HKEX 2269

About WuXi Biologics (Cayman) Inc.

http://www.wuxibiologics.com

WuXi Biologics (Cayman) Inc. operates as a leading global open-access biologics technology platform, offering comprehensive, end-to-end solutions for the discovery, development, and cGMP manufacture of biologics. The company's mission is to accelerate and transform the creation of novel therapies by providing services across the entire biologics lifecycle. Key service areas include mammalian cell culture, monoclonal antibodies, bispecific and multispecific antibodies, Fc-fusion proteins, and specialized bioconjugates such as Antibody Drug Conjugates (ADCs). Utilizing proprietary discovery platforms and advanced Chemistry, Manufacturing, and Controls (CMC) expertise, WuXi Biologics empowers partners globally to efficiently advance their drug candidates from concept to commercialization.

Recent filings

Filing Released Lang Actions
INSIDE INFORMATION - PRESENTATION AT 2026 BUSINESS UPDATE MEETING
Investor Presentation Classification · 94% confidence The document is an announcement that includes the full slide deck of a “2026 Business Update” presentation, featuring forward‐looking statements, adjusted financial measures, technology and business updates, pipeline data, and strategy. It is not a simple notice or link to another report, nor actual financial statements but a detailed investor‐focused presentation delivered at a business update meeting. This matches the definition of an Investor Presentation (IP).
2026-05-31 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is a Hong Kong Stock Exchange ‘Next Day Disclosure Return’ (Form FF305), detailing changes in issued shares, treasury shares, and on-market share repurchases by WuXi Biologics. It provides quantitative repurchase data under Main Board Rules (e.g., 13.25A, 10.06), confirmation by an officer, and detailed repurchase sections. This matches the definition for Transaction in Own Shares (Code: POS) – a report of the company buying back or selling its own shares.
2026-05-29 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is Hong Kong Exchange Form FF305 “Next Day Disclosure Return” under Main Board Rule 13.25A/GEM Rule 17.27A, reporting changes in issued shares (exercise of share options) and detailed on-market share repurchases and treasury share sales, including quantities, prices and confirmations. This is a company’s own share transaction disclosure rather than an annual report, earnings release or proxy material. Therefore it falls under Transaction in Own Shares.
2026-05-28 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 85% confidence The document is a Hong Kong Stock Exchange “Next Day Disclosure Return” (Form FF305) detailing changes in the company’s issued shares and treasury shares – specifically issues of new shares under share schemes, transfers of treasury shares, and on-market share repurchases. This is not an annual or interim report but a regulatory announcement of share issuances and buybacks. Under FinancialReports taxonomy, this falls under “Transaction in Own Shares” (POS), which covers reports of the company buying back or selling its own shares.
2026-05-27 English
VOLUNTARY ANNOUNCEMENT - PROPOSED ON-MARKET SHARE REPURCHASE
Transaction in Own Shares Classification · 90% confidence The document is a voluntary announcement by WuXi Biologics regarding its proposed on-market share repurchase under the existing repurchase mandate. It details the Board’s resolution to repurchase the company’s own shares, the aggregate amount, and the compliance framework. This fits the definition of Transaction in Own Shares (Code: POS).
2026-05-26 English
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON WEDNESDAY, JUNE 10, 2026
AGM Information Classification · 95% confidence The document is a Form of Proxy for the Annual General Meeting (AGM) of WuXi Biologics (Cayman) Inc. It includes instructions for shareholders to appoint proxies to vote on resolutions at the AGM, including receiving the audited financial statements, re-electing directors, appointing auditors, and granting mandates to the board. The document is procedural and related to voting at the AGM rather than the actual AGM materials or financial reports. It is not the AGM presentation or the annual report itself, but a proxy form for voting at the AGM. Therefore, it fits the category of AGM Information (AGM-R), which includes materials shared during the AGM such as proxy forms.
2026-05-19 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.